• Home
  • Our Capabilities
  • Our People
    • Naomi Pearce
    • Jacinta Flattery O’Brien PhD
    • Jennifer Enmon PhD JD
    • Grant Shoebridge PhD
    • Kadri Elcoat
    • Kate Legge
    • Lesley White
    • Alex May
    • Christopher Coates
    • Jessica Chadbourne PhD
    • Joanne Grant
    • Emily Bristow
    • Brittany Deleon
    • Ana Maria Chaves
    • Erni Othman
    • Amber Cross
  • News
    • Pearce IP Blog
    • BioBlast™
  • Blog
  • BioBlast™
  • Contact Us

Lupin biosimilar etanercept Etera® and Rymti® approved

by Bioblast Editor | Oct 1, 2020 | Biosimilars updates

Lupin receives approval for biosimilar etanercept in Australia under the trade names Etera® and Rymti® in PFS presentations.

Merck announces Health Canada approval of Brenzys® for indications

by Bioblast Editor | Sep 15, 2020 | Biosimilars updates

Merck announced Health Canada has approved Brenzys® (biosimilar etanercept) for four new indications: adult patients with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy pediatric patients ages 4 to 17 years...

Lupin and Mylan launch Nepexto® in Germany

by Bioblast Editor | Aug 26, 2020 | Biosimilars updates

Lupin and Mylan launch Nepexto® (biosimilar etanercept) in Germany. Nepexto® is indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, severe axial spondyloarthritis and plaque psoriasis.

Pfizer Q2 FY20 financial results released

by Bioblast Editor | Jul 28, 2020 | Biosimilars updates

Pfizer releases its Q2 FY20 financial results. Pfizer reported a 16% decrease in international revenues for Enbrel® (etanercept), attributing this decrease to biosimilar competition in Europe, Japan and Brazil. 

Sandoz responds to US Court of Appeals judgement upholding judgement of Amgen etanercept patents valid

by Bioblast Editor | Jul 1, 2020 | Biosimilars updates

Sandoz responds to the US Court of Appeals judgment which upheld a ruling from the New Jersey District Court which declared the Amgen patents relating to (etanercept) valid. Sandoz stated that it will continue its efforts to make Erelzi® available in the US, and is...
Page 1 of 1012345...10...»Last »

SUBSCRIBE TO PEARCE IP

Sign up to our latest news

Receive our Pearce IP Blog and weekly BioBlast™ via email.

SUBSCRIBE
  • Our People
  • Our Capabilities
  • News
  • Blog
  • BioBlast™
  • Contact Us
  • Follow

Copyright © 2021 Pearce IP. All Rights Reserved.

Contact Us

Email: info@pearceIP.law
Tel: +61 (0) 2 9023 9988

For any general inquiries, please fill in the following contact form:

 





    Subscribe to our BioBlast™

    Fill in the form below to recieve our BioBlast™ Updates, Pearce IP Blog and other relevant industry updates.

     



      What emails do you want to receive?